{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:17:34Z","timestamp":1787728654440,"version":"build-2784847793"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T00:00:00Z","timestamp":1570406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"LASER ANALYTICA"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0222762","type":"journal-article","created":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T13:27:20Z","timestamp":1570454840000},"page":"e0222762","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5494-6924","authenticated-orcid":true,"given":"Annachiara","family":"Bellin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Berto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakis","family":"Themistoclakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aastha","family":"Chandak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9352-4046","authenticated-orcid":true,"given":"Pietro","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Bakshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Tessarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Deambrosis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Chinellato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,10,7]]},"reference":[{"key":"pone.0222762.ref001","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1378\/chest.11-2888","article-title":"The global burden of atrial fibrillation and stroke: A systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe","author":"GYH Lip","year":"2012","journal-title":"Chest"},{"key":"pone.0222762.ref002","unstructured":"Sanit\u00e0, Istituto Superiore di. Il Progetto Cuore. Progetto cuore.iss. [Online] 02 11 2018. http:\/\/www.cuore.iss.it\/."},{"key":"pone.0222762.ref003","unstructured":"Inzitari D, Polizzi BM, Roti L, Il Progetto FAI: La Fibrillazione Atriale in Italia. La Medicina di Iniziativa e il Medico di Medicina Generale per garantire l\u2019accesso a servizi e cure efficaci riducendo i costi per il SSN e i costi sociali legati all\u2019elevato rischio di ictus cerebrale. 2017."},{"key":"pone.0222762.ref004","year":"2009","journal-title":"Bollettino informativo SER del Veneto"},{"key":"pone.0222762.ref005","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.amjcard.2016.06.009","article-title":"Contemporary Burden of Atrial Fibrillation and Associated Mortality in Northeastern Italy","author":"U Fedeli","year":"2016","journal-title":"American Journal of Cardiology"},{"key":"pone.0222762.ref006","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study","author":"SS Chugh","year":"2014","journal-title":"Circulation"},{"key":"pone.0222762.ref007","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/hrt.2002.008748","article-title":"Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK","author":"S Stewart","year":"2004","journal-title":"Heart"},{"issue":"8","key":"pone.0222762.ref008","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"PA Wolf","year":"1991","journal-title":"Stroke"},{"issue":"12","key":"pone.0222762.ref009","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"RG Hart","year":"2007","journal-title":"Annals of internal medicine"},{"key":"pone.0222762.ref010","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"RE-LY Steering Commit- tee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"SJ Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"pone.0222762.ref011","first-page":"365","article-title":"ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation","author":"CB Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"pone.0222762.ref012","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"ROCKET AF Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"pone.0222762.ref013","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Investigators EA-T. Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"RP Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"pone.0222762.ref014","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40264-017-0592-4","article-title":"From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging Sources","author":"G. Trifir\u00f2","year":"2018","journal-title":"Drug Safety"},{"key":"pone.0222762.ref015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40264-018-0732-5","article-title":"The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?","author":"G Trifir\u00f2","year":"2019","journal-title":"Drug Safety"},{"key":"pone.0222762.ref016","first-page":"37","article-title":"ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","author":"P Kirchhof","year":"2016","journal-title":"European heart journal"},{"key":"pone.0222762.ref017","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1515\/acph-2017-0016","article-title":"Real-practice thromboprophylaxis in atrial fibrillation","author":"P Deambrosis","year":"2017","journal-title":"Acta Pharmaceutica"},{"issue":"21","key":"pone.0222762.ref018","first-page":"2","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"CT January","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"pone.0222762.ref019","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1160\/TH11-11-0784","article-title":"Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a real world atrial fibrillation population: a modelling analysis based on a nationwide cohort study","volume":"107","author":"A Banerjee","year":"2012","journal-title":"Thrombosis and haemostasis"},{"key":"pone.0222762.ref020","first-page":"254","article-title":"Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in real-world atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients","author":"MA Esteve-Pastor","year":"2018","journal-title":"International journal of cardiology"},{"key":"pone.0222762.ref021","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1161\/STROKEAHA.117.017549","article-title":"Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis","author":"G Ntaios","year":"2017","journal-title":"Stroke"},{"key":"pone.0222762.ref022","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1016\/S2352-3026(15)00027-7","article-title":"Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study","author":"K Bouillon","year":"2015","journal-title":"The Lancet Haematology"},{"key":"pone.0222762.ref023","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bcp.12391","article-title":"Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care\u2013results from the D resden NOAC registry","author":"J Beyer-Westendorf","year":"2014","journal-title":"British journal of clinical pharmacology"},{"key":"pone.0222762.ref024","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3111\/13696998.2012.680555","article-title":"Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and","author":"S Deitelzweig","year":"2012","journal-title":"ARISTOTLE trials. Journal of medical economics"},{"key":"pone.0222762.ref025","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jval.2013.01.009","article-title":"Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation","author":"D Coyle","year":"2013","journal-title":"Value in health"},{"key":"pone.0222762.ref026","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1161\/STROKEAHA.111.000402","article-title":"Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation","author":"AR Harrington","year":"2013","journal-title":"Stroke"},{"key":"pone.0222762.ref027","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40261-013-0144-3","article-title":"Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis","author":"C Rognoni","year":"2014","journal-title":"Clinical Drug Investigation"},{"key":"pone.0222762.ref028","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","author":"JA L\u00f3pez-L\u00f3pez","year":"2017","journal-title":"BJM"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0222762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T19:38:52Z","timestamp":1588966732000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0222762"}},"subtitle":[],"editor":[{"given":"Michael","family":"Nagler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,10,7]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0222762","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,7]]}}}